Comparative Pharmacology
Head-to-head clinical analysis: NAFCILLIN SODIUM versus PENICILLIN 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAFCILLIN SODIUM versus PENICILLIN 2.
NAFCILLIN SODIUM vs PENICILLIN-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nafcillin exerts bactericidal activity by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
1-2 g IV every 4 hours; or 1-2 g IM every 4-6 hours.
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
None Documented
None Documented
Approximately 0.5 hour (30 minutes) in adults with normal renal function; prolonged to 1-2 hours in neonates or severe renal impairment. Clinically relevant for dosing every 4-6 hours.
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
Primarily renal (30-40% unchanged) and hepatic/biliary elimination. Approximately 10-15% excreted in bile via feces.
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic